Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
FWP's Cash-to-Debt is ranked higher than
72% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. FWP: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
FWP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39  Med: No Debt Max: No Debt
Current: No Debt
0.39
No Debt
Interest Coverage 660.78
FWP's Interest Coverage is ranked higher than
64% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. FWP: 660.78 )
Ranked among companies with meaningful Interest Coverage only.
FWP' s Interest Coverage Range Over the Past 10 Years
Min: 410.15  Med: 5205.08 Max: No Debt
Current: 660.78
410.15
No Debt
Piotroski F-Score: 5
Altman Z-Score: 4.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
ROE % 265.36
FWP's ROE % is ranked higher than
100% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. FWP: 265.36 )
Ranked among companies with meaningful ROE % only.
FWP' s ROE % Range Over the Past 10 Years
Min: -63.02  Med: -19.3 Max: 747.18
Current: 265.36
-63.02
747.18
ROA % 224.74
FWP's ROA % is ranked higher than
100% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. FWP: 224.74 )
Ranked among companies with meaningful ROA % only.
FWP' s ROA % Range Over the Past 10 Years
Min: -1786.17  Med: -18.7 Max: 669.04
Current: 224.74
-1786.17
669.04
ROC (Joel Greenblatt) % 641137.84
FWP's ROC (Joel Greenblatt) % is ranked higher than
100% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. FWP: 641137.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FWP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -448940  Med: -139362.52 Max: 848140.71
Current: 641137.84
-448940
848140.71
GuruFocus has detected 1 Warning Sign with Forward Pharma A/S FWP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FWP's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

FWP Guru Trades in Q2 2017

Seth Klarman 6,364,059 sh (+14.15%)
Steven Cohen Sold Out
» More
Q3 2017

FWP Guru Trades in Q3 2017

Jim Simons 181,900 sh (New)
Seth Klarman 6,463,265 sh (+1.56%)
» More
Q4 2017

FWP Guru Trades in Q4 2017

Jim Simons 193,100 sh (+6.16%)
Seth Klarman 4,179,940 sh (-35.33%)
» More
Q1 2018

FWP Guru Trades in Q1 2018

Seth Klarman 2,848,003 sh (-31.86%)
Jim Simons 130,100 sh (-32.63%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:FWP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2018-03-31 Reduce -31.86%0.05%$2.17 - $5.36 $ 3.33-4%2,848,003
Seth Klarman 2018-01-31 Reduce -31.86%0.04%Premium Member Access $3.4 $ 3.33-2%2,848,003
Seth Klarman 2017-12-31 Reduce -35.33%0.17%$3.44 - $7.1 $ 3.33-34%4,179,940
Seth Klarman 2017-09-30 Add 1.56%0.01%$5.5 - $28.47 $ 3.33-83%6,463,265
Seth Klarman 2017-06-30 Add 14.15%0.18%$18.7 - $21.96 $ 3.33-83%6,364,059
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:ACER, NAS:MDWD, NAS:VTVT, AMEX:PFNX, XKRX:041910, XCNQ:THC, NAS:EVFM, NAS:CDMO, XKRX:043090, TSE:7776, OTCPK:RASP, TPE:1786, LSE:BVXP, NAS:CFRX, NAS:CKPT, OTCPK:ARPO, OSL:PCIB, LSE:TRX, XTER:CNWK, NAS:PSTI » details
Traded in other countries:1FPA.Germany,
Headquarter Location:Denmark
Forward Pharma A/S is a Danish biopharmaceutical company preparing to initiate a clinical trial using FP187, a proprietary formulation of dimethyl fumarate, or DMF, for the treatment of multiple sclerosis, or MS, patients.

Forward Pharma A/S is a biopharmaceutical company which engages in the research and production of a medicinal treatment for multiple sclerosis and psoriasis. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company is engaged in segments of the pharmaceutical and biotechnological industries. Forward Pharma is actively developing FP187, a proprietary formulation of dimethyl fumarate ("DMF"), for the treatment of multiple sclerosis ("MS") patients. The company has conducted a pre-clinical program and has completed several Phase I and Phase II clinical trials for the product FP187.

Top Ranked Articles about Forward Pharma A/S

Merger Arbitrage Positions Dominate Seth Klarman's Equity Portfolio Klarman is betting on several deals to complete
Over the past few days, hedge fund investors with more than $100 million have been filing their 13F reports with the SEC, updating the regulator on their positions' movements during the first quarter of 2018. Read more...
Forward Pharma Appeals the Decision of the Opposition Division to Revoke the EP2801355 Patent
Forward Pharma Reports Full-Year 2017 Financial and Operational Results
Forward Pharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference
Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent
Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent
Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit
Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit
Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018
Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018

Ratios

vs
industry
vs
history
PE Ratio 2.37
FWP's PE Ratio is ranked higher than
94% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. FWP: 2.37 )
Ranked among companies with meaningful PE Ratio only.
FWP' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.9
Current: 2.37
0
2.9
PE Ratio without NRI 2.37
FWP's PE Ratio without NRI is ranked higher than
95% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. FWP: 2.37 )
Ranked among companies with meaningful PE Ratio without NRI only.
FWP' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.9
Current: 2.37
0
2.9
PB Ratio 1.77
FWP's PB Ratio is ranked higher than
100% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. FWP: 1.77 )
Ranked among companies with meaningful PB Ratio only.
FWP' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.18
Current: 1.77
0
2.18
Price-to-Free-Cash-Flow 1.45
FWP's Price-to-Free-Cash-Flow is ranked higher than
96% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. FWP: 1.45 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
FWP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.77
Current: 1.45
0
1.77
Price-to-Operating-Cash-Flow 1.45
FWP's Price-to-Operating-Cash-Flow is ranked higher than
97% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. FWP: 1.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
FWP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.77
Current: 1.45
0
1.77
Current Ratio 5.21
FWP's Current Ratio is ranked higher than
59% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. FWP: 5.21 )
Ranked among companies with meaningful Current Ratio only.
FWP' s Current Ratio Range Over the Past 10 Years
Min: 0.05  Med: 5.21 Max: 32.04
Current: 5.21
0.05
32.04
Quick Ratio 5.21
FWP's Quick Ratio is ranked higher than
61% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. FWP: 5.21 )
Ranked among companies with meaningful Quick Ratio only.
FWP' s Quick Ratio Range Over the Past 10 Years
Min: 0.05  Med: 5.21 Max: 32.04
Current: 5.21
0.05
32.04

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 41.20
FWP's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. FWP: 41.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FWP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: 41.2  Med: 0 Max: 0
Current: 41.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.66
FWP's Price-to-Net-Cash is ranked higher than
100% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. FWP: 1.66 )
Ranked among companies with meaningful Price-to-Net-Cash only.
FWP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.18  Med: 39.07 Max: 54.82
Current: 1.66
1.18
54.82
Price-to-Net-Current-Asset-Value 1.64
FWP's Price-to-Net-Current-Asset-Value is ranked higher than
100% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. FWP: 1.64 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
FWP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.16  Med: 37.15 Max: 53.41
Current: 1.64
1.16
53.41
Price-to-Tangible-Book 1.76
FWP's Price-to-Tangible-Book is ranked higher than
100% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. FWP: 1.76 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
FWP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 22.24 Max: 25.2
Current: 1.76
1.16
25.2
Price-to-Graham-Number 0.36
FWP's Price-to-Graham-Number is ranked higher than
99% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.76 vs. FWP: 0.36 )
Ranked among companies with meaningful Price-to-Graham-Number only.
FWP' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.16  Med: 0.26 Max: 0.47
Current: 0.36
0.16
0.47

More Statistics

EPS (TTM) $ 1.45
Beta2.31
Volatility48.68%
52-Week Range $1.63 - 30.00
Shares Outstanding (Mil)47.18 (ADR)

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 170 195
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 2.98 2.20
EPS without NRI ($) 2.98 2.20
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}